Stephen Sinclair, M.D. – is the founding co-director of Sinclair Technologies LLC, GSX Pharma, and a consultant for AI Spectral. Dr. Sinclair also serves as a medical advisor to the American Optometric Association's Committee, where he supports the development of guidelines for managing macular disease.

Dr. Sinclair is a graduate of the University of Pennsylvania and a Thouron Scholar at Cambridge University. After graduating from Harvard Medical School, Dr. Sinclair trained at the Massachusetts Eye and Ear Infirmary and completed his fellowship in vitreo-retinal surgery at the University of Wisconsin.Dr. Sinclair practiced full-time in academic vitreoretinal surgery for 20 years, first at the Univ of Pennsylvania and then at Drexel-Hahnemann Medical School, where he later served as Chairman.

Starting in 1998, Dr. Sinclair worked in private practice as a vitreoretinal surgeon and until recently served as Adjunct Professor at the Pennsylvania College of Optometry and College of Engineering, Drexel University. Dr. Sinclair has taught ophthalmic surgeons around the world through Project Orbis and teaches multiple surgical specialties regarding the enhancement of vision for surgical endoscopic dissection, having developed the first surgical simulator and subsequently consulted with the development of VR Magic, the current leader in ophthalmic surgical simulation.

Today, Dr. Sinclair’s research continues, focusing on the development of numerous digital devices including the laser doppler measurement of retinal blood flow, the measurement of resolution visual fields under real world luminance and contrast conditions, and the development of ophthalmic image management and annotation systems to improve the viewing and comparison images across different ophthalmic testing devices overtime using artificial intelligence.  Dr. Sinclair has received Honor and Senior Achievement Awards from the American Academy of Ophthalmology and the American Society of Retinal Specialists. To date, he has published more than 100 original scientific papers and holds +12 device and drug patents.

Igor Kozak, MD, PhD is professor of ophthalmology at the University of Arizona School of Medicine, specializing in consultation and surgery for disorders of the retina, vitreous, and macula. Dr. Kozak is a graduate of Pavol Jozef Šafárik University in Slovakia and is a fellowship-trained retina and uveitis specialist from the University of California San Diego Shiley Eye Institute, where he served on the retina faculty. He subsequently served as Consultant Ophthalmic Surgeon and Clinical Lead at the Moorfields Eye Hospital Centre in Abu Dhabi, United Arab Emirates, where he attended patients with retinal and inflammatory diseases and performing vitreoretinal surgery on adults and children.

Dr. Kozak’s academic interests include clinical research, ocular imaging, drug delivery, pharmacology, retinal laser treatment, and telemedicine. He has participated in numerous clinical trials as associate and principal investigator. He has published extensively in premier ophthalmic and scientific journals and has edited 6 ophthalmic books internationally. He serves as a scientific reviewer for more than 50 ophthalmology journals and is an editorial board member for 4 journals.

Matthew Ward, MD is an eye surgeon and cornea specialist practicing at the Riverwoods Eye Center in Provo, UT. He attended medical school at the University of Utah and completed residency and fellowship training at the world-renowned University of Iowa Department of Ophthalmology. Prior to medical school he was a research fellow at Harvard Medical School’s Schepens Eye Research Institute and an undergraduate at Brigham Young University.

Dr. Ward has a special interest in innovation that simplifies clinical practice, reduces costs and improves patient care. He has published novel surgical techniques in peer-reviewed literature, designed surgical instruments and devices and is a named inventor on several patents. Dr. Ward is a member of the American Academy of Ophthalmology and board certified by the American Board of Ophthalmology.

Vicente Diaz, MD specializes in ocular inflammatory and infectious diseases. Dr. Diaz’ practice also includes Comprehensive Ophthalmology, treating ailments such as Dry Eye Syndrome, Glaucoma, and Cataracts. His research interests include novel immunomodulatory therapies for the treatment of non-infectious inflammatory disease, management of Stevens Johnson’s Syndrome, a potentially lethal autoimmune disease, and innovative therapies in glaucoma.

Dr. Diaz is Chief of Ophthalmology at the Yale Health Plan, addressing the eye needs of the Yale faculty, students, employees, and their families. He is the Director of Diversity and Inclusion for the Department of Ophthalmology and Visual Science at Yale University. Dr. Diaz is also Director of Ophthalmology for the Bridgeport Hospital Burn Unit, where he oversees the care of all patients with Stevens Johnson's Syndrome in the state of Connecticut.

Dr. Diaz was voted among the top eye doctors in Fairfield County in the Fairfield Advocate’s 2012 and 2013 reader’s polls. After graduating from Ophthalmology residency at Yale University, he completed a fellowship in Ocular Immunology & Infectious Disease at The New York Eye & Ear Infirmary where he was recently on the clinical and research faculty. He is currently a co-investigator on several FDA clinical trials of novel immunomodulatory therapies for inflammatory diseases, sponsored by companies such as Abott, Novartis, and Lux Biosciences.

Dr. Diaz is also active in the surrounding community, with a presence that has grown consistently throughout his tenure in the Tri-State, including an appointment as keynote speaker at the 2011 Puerto Rican Festival in Bridgeport, Connecticut. Dr. Diaz founded the La Unidad Latina Medical Guild and was the architect of their annual medical mission to the Dominican Republic, Guatemala, and Honduras where he performs surgery, teaches medical residents, and cares for patients in need; the team created by Dr. Diaz sees between 3,000 – 5,000 patients abroad annually. Dr. Diaz received his BA from Brown University, his MD from Yale School of Medicine, and his MBA at Yale School of Management.